U.S. stock market intraday update: OSR up 124.29%

U.S. Stock Market Midday Update

OSR rose 124.29%, with active trading. Based on recent important news:

1. On July 8, OSR Holdings obtained a $80 million equity credit line, enhancing the company's financial strength, leading to a rise in stock price.

2. On July 25, OSL Group completed a $300 million equity financing, pushing the stock price up by 5.72%.

3. On August 5, after resuming trading, Shangwei New Materials' stock price surged by 14%, reflecting high market sentiment.

Stocks with High Trading Volume in the Industry

HCW Biologics rose 57.93%, with a trading volume of $124 million. Based on recent important news:

1. On August 25, the company’s immune checkpoint inhibitor based on pembrolizumab showed success in IND-enabled studies for solid tumors, activating immune cells and promoting their infiltration, leading to a significant stock price increase of 57.93%.

ESSA Pharmaceuticals fell 59.23%, with increased trading volume. Based on recent important news:

1. On July 18, Federal Pharmaceuticals announced a placement of new shares, causing the stock price to drop by 7.15%. This move may affect market confidence in the pharmaceutical industry, leading to a significant decline in ESSA Pharmaceuticals' stock price.

2. On August 1, Kangmei Pharmaceutical experienced a block trade at a discount of 11.37%, impacting market confidence in the pharmaceutical industry.

3. On August 19, frequent block trades in Borui Pharmaceuticals led to a 1.97% drop in stock price, affecting market sentiment.

Ethzilla rose 8.94%, with increased trading volume. Based on recent important news:

1. On August 25, ETHZilla announced a $250 million stock buyback plan, effective immediately, pushing the stock price up by 6.06%.

2. On August 23, ETHZilla raised the scale of its stock issuance to $10 billion to support the purchase of ETH, enhancing market confidence.

3. On August 22, ETHZilla shareholders applied for the issuance of 74.8 million convertible stocks, leading to stock price fluctuations.

Stocks with High Market Capitalization in the Industry

AbbVie fell 0.06%, with increased trading volume. Based on recent important news:

1. On August 22, AbbVie announced that its alopecia treatment drug Rinvoq achieved its primary goals in late-stage trials, showing significant efficacy and manageable risks, stabilizing the stock price.

2. On August 25, AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' antidepressant for $1.2 billion, expanding its psychiatry product line and enhancing market confidence.

3. On August 24, analysts predicted that AbbVie's Skyrizi and Rinvoq would drive the company's long-term growth, despite Humira losing patent protection, still achieving revenue growth